Brentuximab vedotin in patients with Hodgkin Lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four italian centers

Oncologist

Volumn 20, Issue 3, 2015, Pages 323-328

  Carlo Stella, Carmelo ^a,b   Rcci, Francesca ^a   Dalto, S Erena ^d   Mazza, Rita ^a   Malagola, Michele ^e   Patriarca, Francesca ^f   Viviani, Simonetta ^d   Russo, Domenico ^e   Giordano, Laura ^a   Castagna, Luca ^a   Corradini, Paolo ^c,d   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Departments of Medical Biotechnology and Translational Medicine   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f Azienda Ospedaliera Universitaria   (Italy)

Author keywords

Allogeneic stem cell transplantation; Brentuximab vedotin; CD30; Relapsed or refractory Hodgkin lymphoma; Targeted therapy

Indexed keywords

BRENTUXIMAB VEDOTIN; COTRIMOXAZOLE; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER CENTER; CANCER REGRESSION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL SENSORY NEUROPATHY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; YOUNG ADULT; CLINICAL TRIAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ITALY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; ITALY; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84925454228     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0420     Document Type: Article

References (38)

1. Canellos GP, Rosenberg SA, Friedberg JW et al. Treatment of Hodgkin lymphoma: A 50-year perspective. J Clin Oncol 2014;32:163-168.
2. Moskowitz AJ, Perales M-A, Kewalramani T et al. Outcomes for patients who fail high dose chemo-radiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009;146:158-163.
3. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology (Am Soc Hematol Educ Program) 2008; 1:326-333.
4. Martínez C, Canals C, Sarina B et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autol-ogousstem cell transplantation. Ann Oncol 2013;24: 2430-2434.
5. Arai S, Fanale M, DeVos S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013;54: 2531-2533.
6. Canellos GP. Brentuximab vedotin and panobi-nostat: New drugs for Hodgkin’s lymphoma—can they make one of medical oncology’s chemotherapy success stories more successful? J Clin Oncol 2012; 30:2171-2172.
7. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program) 2009; 1:507–519.
8. Younes A. Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011;8:85–96.
9. Younes A, Bartlett NL, Leonard JP et al. Brentuxi-mab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
10. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183–2189.
11. Sarina B, Castagna L, Farina L et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability. Blood 2010;115: 3671–3677.
12. Sureda A, Robinson S, Canals C et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455–462.
13. Robinson SP, Sureda A, Canals C et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: Identification of prognostic factors predicting outcome. Haema-tologica 2009;94:230–238.
14. Armand P, Kim HT, Ho VT et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome. Biol Blood Marrow Transplant 2008;14:418–425.
15. Corradini P, Dodero A, Farina L et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007;21:2316–2323.
16. Ram R, Gooley TA, Maloney DG et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17: 1537–1545.
17. Corazzelli G, Angrilli F, D’Arco A et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013;160:207-215.
18. Anastasia A, Carlo-Stella C, Corradini P et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: A retrospective study of the Fondazione Italiana Linfomi. Br J Haematol 2014; 166:140-142.
19. Younes A, Sureda A, Ben-Yehuda D et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol 2012;30:2197-2203.
20. Johnston PB, Inwards DJ, Colgan JP et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85:320-324.
21. Fehniger TA, Larson S, Trinkaus K et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118:5119-5125.
22. Gopal AK, Ramchandren R, O’Connor OA et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120:560-568.
23. Katz J, Janik JE, Younes A. Brentuximabvedotin (SGN-35). Clin Cancer Res 2011;17:6428-6436.
24. Theurich S, Malcher J, Wennhold K et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013;31:e59-e63.
25. Cheson BD, Pfistner BJ uweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
27. Rothe A, Sasse S, Goergen H et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: The German Hodgkin Study Group experience. Blood 2012;120:1470-1472.
28. Zinzani PL, Viviani S, Anastasia A et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: The Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013;98:1232-1236.
29. Gibb A, Jones C, Bloor A et al. Brentuximab vedotin in refractory CD30+ lymphomas: A bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013;98:611-614.
30. Illidge T, Bouabdallah R, Chen R et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma 2014;1–34.
31. Wudhikarn K, Brunstein CG, Bachanova V et al. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: Management strategies and outcome. Biol Blood Marrow Transplant 2011; 17:1497-1504.
32. Moskowitz AJ, Hamlin PA Jr., Perales MA et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31: 456-460.
33. Sala E, Crocchiolo R, Gandolfi S et al. Bendamustine combined with donor lymphocytes infusion in Hodgkin’s lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014;20: 1444-1447.
34. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934-1941.
35. Sureda A, Canals C, Arranz R et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-317.
36. Anderlini P, Saliba R, Acholonu S et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: The updated M.D. Anderson Cancer Center experience. Haematologica 2008;93: 257-264.
37. Chen YB, McDonough S, Hasserjian R et al. Expression of CD30 in patients with acute graft-versus-host disease. Blood 2012;120:691-696.
38. Bartlett NL, Chen R, Fanale MA et al. Retreat-ment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014;7:24.